Impact of Dose, Liver Function, and Nutrition on 5-FU Clearance
Author Information
Author(s): R.A. Fleming, G.A. Milano, M.-C. Etienne, N. Renee, A. Thyss, M. Schneider, F. Demard
Primary Institution: Laboratoire d'Oncopharmacologie, Centre Antoine-Lacassagne, Nice, France
Hypothesis
Does 5-FU dose, hepatic function, or nutritional status affect its clearance in patients with head and neck cancer?
Conclusion
5-FU clearance is not affected by dose, hepatic function, or nutritional status.
Supporting Evidence
- Significant interpatient variability in 5-FU clearance was observed, with a ten-fold range.
- 5-FU clearance was not modified by dose, indicating linear pharmacokinetics.
- Laboratory data on hepatic function and nutritional status did not correlate with 5-FU clearance.
Takeaway
This study found that changing the dose of a cancer drug called 5-FU doesn't change how quickly it's cleared from the body, even if the liver isn't working well or if a person isn't eating properly.
Methodology
The study analyzed 222 cycles of therapy in 187 patients with head and neck cancer, measuring 5-FU pharmacokinetics and correlating them with dose, hepatic function, and nutritional status.
Limitations
The study did not assess the impact of 5-FU on toxicities like mucositis and leukopenia, and the population may not reflect patients with severe liver dysfunction.
Participant Demographics
187 patients (155 males, 32 females) with a median age of 62 years (range 35-85).
Statistical Information
P-Value
0.124
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website